Enzalutamide Tablets 160mg
ENZALIEVA Enzalutamide Tablets 160mg is an advanced anticancer medicine used for the treatment of prostate cancer in adult patients. It contains Enzalutamide, a powerful androgen receptor inhibitor that helps slow down the growth and spread of prostate cancer cells. This medicine is commonly prescribed by oncologists as part of hormone therapy for patients suffering from advanced or metastatic prostate cancer.
Prostate cancer is one of the most common cancers affecting men worldwide. Cancer cells in the prostate often depend on male hormones called androgens, especially testosterone, for growth and survival. Enzalutamide works by blocking the action of these hormones, helping reduce the ability of cancer cells to grow and multiply. Due to its targeted mechanism of action, ENZALIEVA is widely used in modern oncology treatment protocols for prostate cancer management.
ENZALIEVA Enzalutamide Tablets 160mg is manufactured under strict pharmaceutical quality standards to ensure safety, effectiveness, and consistent therapeutic performance. The medicine is commonly recommended in patients with:
Metastatic castration-resistant prostate cancer (mCRPC)
Non-metastatic castration-resistant prostate cancer (nmCRPC)
Metastatic hormone-sensitive prostate cancer (mHSPC)
This anticancer medicine is usually prescribed when prostate cancer continues to progress despite reduced testosterone levels or hormonal treatment. Doctors may use ENZALIEVA alone or in combination with other therapies depending on the patient’s condition, cancer stage, and overall treatment plan.
Enzalutamide Tablets are known for helping improve disease management by delaying cancer progression and supporting overall treatment outcomes. The medicine has become an important part of prostate cancer therapy due to its effectiveness in controlling androgen receptor activity, which plays a major role in prostate cancer growth.
Patients should use this medicine strictly under the supervision of qualified healthcare professionals. Proper medical monitoring and regular health checkups are important during treatment to ensure better response and patient safety.
View Details
Bicalutamide Tablet IP 50mg
BICALIEVA 50MG (Bicalutamide Tablet IP 50mg) is a prescription anti-cancer medicine used in the treatment and management of prostate cancer. It contains Bicalutamide 50mg, a non-steroidal antiandrogen that works by blocking the effects of male hormones (androgens), particularly testosterone, which can stimulate the growth of prostate cancer cells.
Prostate cancer is one of the most commonly diagnosed cancers in men worldwide. Many prostate cancer cells rely on testosterone and other androgens to grow and multiply. BICALIEVA 50MG helps control the disease by preventing these hormones from attaching to cancer cells, thereby slowing cancer growth and reducing tumor progression.
Bicalutamide is widely used as part of hormone therapy for prostate cancer and is often prescribed in combination with other treatments such as luteinizing hormone-releasing hormone (LHRH) agonists or surgical castration. This combined approach helps achieve more effective androgen deprivation, which is an important strategy in prostate cancer management.
BICALIEVA 50MG is commonly prescribed for:
• Advanced Prostate Cancer
• Metastatic Prostate Cancer
• Hormone-Sensitive Prostate Cancer
• Androgen Deprivation Therapy (ADT)
• Combination Prostate Cancer Treatment
• Long-Term Oncology and Urology Care
The medicine is manufactured under strict pharmaceutical quality standards to ensure safety, effectiveness, and consistent therapeutic performance. It should only be used under the supervision of qualified healthcare professionals experienced in oncology and urology treatment.
Patients receiving BICALIEVA 50MG may require regular monitoring of prostate-specific antigen (PSA) levels, liver function, overall treatment response, and routine medical evaluations. These assessments help healthcare providers optimize treatment outcomes and manage potential side effects effectively.
Due to its proven role in hormone-based prostate cancer treatment, BICALIEVA 50MG remains an important medicine in modern oncology and urology care programs.
View Details
Abiraterone Acetate Tablets IP 500mg
ABIRALIEVA 500 MG (Abiraterone Acetate Tablets IP 500 mg) is a prescription anticancer medicine containing Abiraterone Acetate 500 mg, a targeted hormonal therapy used primarily for the treatment of prostate cancer. It is commonly prescribed for patients with metastatic castration-resistant prostate cancer (mCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC) as part of a comprehensive oncology treatment plan.
Abiraterone Acetate belongs to a class of medicines known as androgen biosynthesis inhibitors. Prostate cancer cells often depend on male hormones called androgens, particularly testosterone, to grow and multiply. ABIRALIEVA 500 MG works by blocking an enzyme called CYP17 (17α-hydroxylase/C17,20-lyase), which plays a crucial role in the production of androgens in the testes, adrenal glands, and tumor tissues.
By significantly reducing androgen levels throughout the body, Abiraterone helps slow the growth and spread of prostate cancer cells. This targeted mechanism has made it one of the most important advances in the treatment of advanced prostate cancer.
Unlike conventional chemotherapy, Abiraterone specifically targets hormone production pathways associated with prostate cancer progression. It is frequently prescribed alongside corticosteroids such as prednisone or prednisolone to help manage certain treatment-related effects and optimize therapeutic outcomes.
ABIRALIEVA 500 MG is commonly prescribed for:
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Advanced Prostate Cancer
Recurrent Prostate Cancer
Hormone-Driven Prostate Tumors
Long-Term Prostate Cancer Management
Combination Hormonal Therapy Programs
Precision Oncology Treatment Plans
The medicine has become a cornerstone of modern prostate cancer treatment due to its ability to improve disease control and support long-term management strategies.
Manufactured under stringent pharmaceutical quality standards, ABIRALIEVA 500 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Abiraterone therapy typically undergo regular monitoring, including liver function tests, blood pressure assessments, potassium level evaluations, and routine clinical examinations to ensure safe and effective treatment.
Due to its proven clinical efficacy and targeted hormonal action, ABIRALIEVA 500 MG remains an important treatment option in advanced prostate cancer care worldwide.
View Details
Abiraterone Acetate Tablets IP 25mg
ABIRALIEVA 250 MG (Abiraterone Acetate Tablets IP 250 mg) is a prescription anticancer medicine containing Abiraterone Acetate 250 mg, a targeted hormonal therapy widely used in the treatment of advanced prostate cancer. It is specifically designed to help manage prostate cancers that depend on male hormones, known as androgens, for growth and survival.
Prostate cancer is one of the most common cancers affecting men worldwide. In many cases, cancer cells continue to grow even after conventional hormone-lowering treatments. ABIRALIEVA 250 MG helps address this challenge by reducing androgen production throughout the body, thereby slowing cancer progression and helping improve treatment outcomes.
Abiraterone Acetate belongs to a class of medicines called Androgen Biosynthesis Inhibitors. It works by blocking the activity of the CYP17 enzyme, which plays a crucial role in the production of testosterone and other androgens in the adrenal glands, testes, and prostate tumor tissues. By significantly reducing androgen levels, the medicine helps limit the growth and spread of prostate cancer cells.
Unlike traditional chemotherapy, which directly attacks rapidly dividing cells, Abiraterone targets hormone production pathways associated with cancer progression. This targeted mechanism has made it an important component of modern prostate cancer treatment strategies.
ABIRALIEVA 250 MG is commonly prescribed for:
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Advanced Prostate Cancer
Recurrent Prostate Cancer
Hormone-Dependent Prostate Cancer
Long-Term Cancer Management
Combination Hormonal Therapy Programs
Precision Oncology Treatment Plans
The medicine is often used in combination with corticosteroids such as prednisone or prednisolone as recommended by healthcare professionals.
Manufactured according to stringent pharmaceutical quality standards, ABIRALIEVA 250 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Abiraterone therapy require regular monitoring, including liver function tests, blood pressure assessments, potassium level evaluations, and routine clinical examinations to ensure safe and effective treatment.
Due to its proven efficacy and targeted hormonal action, ABIRALIEVA 250 MG has become a trusted treatment option for advanced prostate cancer worldwide.
View Details
Enzalutamide Capsules 40mg
ENZALIEVA 40 MG (Enzalutamide Capsules 40 mg) is a prescription anticancer medicine containing Enzalutamide 40 mg, a next-generation androgen receptor inhibitor used for the treatment of advanced prostate cancer. It is specifically designed to help slow the growth and spread of prostate cancer cells by blocking the effects of male hormones, known as androgens, that fuel cancer progression.
Prostate cancer is one of the most commonly diagnosed cancers in men worldwide. Many prostate cancer cells depend on testosterone and other androgens for survival and growth. Even after treatments that lower testosterone levels, cancer cells may continue to grow by activating androgen receptors. ENZALIEVA 40 MG helps overcome this challenge by directly blocking androgen receptor signaling, thereby reducing the ability of cancer cells to multiply and spread.
Enzalutamide belongs to a class of medicines known as Androgen Receptor Inhibitors. Unlike conventional hormone therapies that primarily reduce testosterone production, Enzalutamide works by preventing androgen receptors from receiving hormonal signals. This dual approach helps provide more effective disease control in advanced stages of prostate cancer.
ENZALIEVA 40 MG is commonly prescribed for:
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC)
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Advanced Prostate Cancer
Recurrent Prostate Cancer
Long-Term Prostate Cancer Management
Hormone-Driven Prostate Tumors
Precision Oncology Treatment Programs
The medicine may be used as part of a comprehensive cancer treatment plan developed by an oncologist based on the patient's medical condition, disease stage, and treatment history.
Manufactured according to stringent pharmaceutical quality standards, ENZALIEVA 40 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Enzalutamide therapy typically require regular monitoring, including blood pressure assessments, liver function evaluations, neurological monitoring, and routine clinical follow-up to ensure safe and effective treatment.
Due to its targeted mechanism of action and proven clinical benefits, ENZALIEVA 40 MG has become an important treatment option in modern prostate cancer care worldwide.
View Details
Enzalutamide Capsules 40mg
ENZALIEVA 40 MG (Enzalutamide Capsules 40 mg) is a prescription medication containing Enzalutamide 40 mg, a next-generation androgen receptor inhibitor used for the treatment of advanced prostate cancer. It is specifically developed to help control the growth and spread of prostate cancer cells by blocking the effects of male hormones (androgens) that play a crucial role in cancer progression.
Prostate cancer is one of the most commonly diagnosed cancers among men worldwide. While many prostate cancers initially respond to hormone-lowering therapies, some cancers eventually continue to grow despite reduced testosterone levels. ENZALIEVA 40 MG helps address this challenge by directly targeting androgen receptor signaling pathways that cancer cells rely on for survival and multiplication.
Enzalutamide works differently from traditional hormone therapies. Instead of only reducing hormone production, it blocks the androgen receptor at multiple stages, preventing cancer cells from receiving and using hormonal signals. This advanced mechanism helps slow tumor growth, delay disease progression, and support long-term disease management.
ENZALIEVA 40 MG is widely prescribed for patients with:
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC)
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Advanced Prostate Cancer
Recurrent Prostate Cancer
Hormone-Driven Prostate Tumors
Long-Term Prostate Cancer Management
Precision Oncology Treatment Programs
The medicine has become an important part of modern prostate cancer treatment because of its proven ability to improve progression-free survival and help maintain quality of life in eligible patients.
Unlike conventional chemotherapy, ENZALIEVA 40 MG specifically targets pathways involved in prostate cancer growth, making it a highly effective option for selected patients. It is often prescribed as part of a comprehensive oncology treatment plan under the supervision of experienced healthcare professionals.
Manufactured according to stringent pharmaceutical quality standards, ENZALIEVA 40 MG is designed to deliver consistent therapeutic performance, safety, and reliability.
Regular follow-up appointments, laboratory testing, and clinical evaluations are important during treatment to monitor effectiveness and manage any potential side effects.
View Details
